Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells

Candice Ashmore-Harris; Madeleine Iafrate; Adeel Saleem; Gilbert O. Fruhwirth

doi:10.1016/j.ymthe.2020.03.016

Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells

Candice Ashmore-Harris, Madeleine Iafrate, Adeel Saleem, Gilbert O. Fruhwirth^*

^*Corresponding author for this work

Imaging Chemistry & Biology

Research output: Contribution to journal › Review article › peer-review

28 Citations (Scopus)

134 Downloads (Pure)

Abstract

Cell therapies represent a rapidly emerging class of new therapeutics. They are intended and developed for the treatment of some of the most prevalent human diseases, including cancer, diabetes, and for regenerative medicine. Currently, they are largely developed without precise assessment of their in vivo distribution, efficacy, or survival either clinically or preclinically. However, it would be highly beneficial for both preclinical cell therapy development and subsequent clinical use to assess these parameters in situ to enable enhancements in efficacy, applicability, and safety. Molecular imaging can be exploited to track cells non-invasively on the whole-body level and can enable monitoring for prolonged periods in a manner compatible with rapidly expanding cell types. In this review, we explain how in vivo imaging can aid the development and clinical translation of cell-based therapeutics. We describe the underlying principles governing non-invasive in vivo long-term cell tracking in the preclinical and clinical settings, including available imaging technologies, reporter genes, and imaging agents as well as pitfalls related to experimental design. Our emphasis is on adoptively transferred T cell and stem cell therapies.

Original language	English
Article number	10.1016/j.ymthe.2020.03.016
Pages (from-to)	1392-1416
Number of pages	25
Journal	Molecular Therapy
Volume	28
Issue number	6
Early online date	20 Mar 2020
DOIs	https://doi.org/10.1016/j.ymthe.2020.03.016
Publication status	Published - 3 Jun 2020

Keywords

adoptive cell therapy
cell tracking
immunotherapy
molecular imaging
prostate-specific membrane antigen
sodium iodide symporter

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ymthe.2020.03.016

Ashmore-Harris et al_MolTher2020_accepted-watermarkAccepted author manuscript, 1.44 MBLicence: CC BY-NC-ND

Cite this

@article{5d3abef47c6c4b96a3c4cf9ab696bbb1,

title = "Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells",

abstract = "Cell therapies represent a rapidly emerging class of new therapeutics. They are intended and developed for the treatment of some of the most prevalent human diseases, including cancer, diabetes, and for regenerative medicine. Currently, they are largely developed without precise assessment of their in vivo distribution, efficacy, or survival either clinically or preclinically. However, it would be highly beneficial for both preclinical cell therapy development and subsequent clinical use to assess these parameters in situ to enable enhancements in efficacy, applicability, and safety. Molecular imaging can be exploited to track cells non-invasively on the whole-body level and can enable monitoring for prolonged periods in a manner compatible with rapidly expanding cell types. In this review, we explain how in vivo imaging can aid the development and clinical translation of cell-based therapeutics. We describe the underlying principles governing non-invasive in vivo long-term cell tracking in the preclinical and clinical settings, including available imaging technologies, reporter genes, and imaging agents as well as pitfalls related to experimental design. Our emphasis is on adoptively transferred T cell and stem cell therapies.",

keywords = "adoptive cell therapy, cell tracking, immunotherapy, molecular imaging, prostate-specific membrane antigen, sodium iodide symporter",

author = "Candice Ashmore-Harris and Madeleine Iafrate and Adeel Saleem and Fruhwirth, {Gilbert O.}",

year = "2020",

month = jun,

day = "3",

doi = "10.1016/j.ymthe.2020.03.016",

language = "English",

volume = "28",

pages = "1392--1416",

journal = "Molecular therapy : the journal of the American Society of Gene Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells

AU - Ashmore-Harris, Candice

AU - Iafrate, Madeleine

AU - Saleem, Adeel

AU - Fruhwirth, Gilbert O.

PY - 2020/6/3

Y1 - 2020/6/3

N2 - Cell therapies represent a rapidly emerging class of new therapeutics. They are intended and developed for the treatment of some of the most prevalent human diseases, including cancer, diabetes, and for regenerative medicine. Currently, they are largely developed without precise assessment of their in vivo distribution, efficacy, or survival either clinically or preclinically. However, it would be highly beneficial for both preclinical cell therapy development and subsequent clinical use to assess these parameters in situ to enable enhancements in efficacy, applicability, and safety. Molecular imaging can be exploited to track cells non-invasively on the whole-body level and can enable monitoring for prolonged periods in a manner compatible with rapidly expanding cell types. In this review, we explain how in vivo imaging can aid the development and clinical translation of cell-based therapeutics. We describe the underlying principles governing non-invasive in vivo long-term cell tracking in the preclinical and clinical settings, including available imaging technologies, reporter genes, and imaging agents as well as pitfalls related to experimental design. Our emphasis is on adoptively transferred T cell and stem cell therapies.

AB - Cell therapies represent a rapidly emerging class of new therapeutics. They are intended and developed for the treatment of some of the most prevalent human diseases, including cancer, diabetes, and for regenerative medicine. Currently, they are largely developed without precise assessment of their in vivo distribution, efficacy, or survival either clinically or preclinically. However, it would be highly beneficial for both preclinical cell therapy development and subsequent clinical use to assess these parameters in situ to enable enhancements in efficacy, applicability, and safety. Molecular imaging can be exploited to track cells non-invasively on the whole-body level and can enable monitoring for prolonged periods in a manner compatible with rapidly expanding cell types. In this review, we explain how in vivo imaging can aid the development and clinical translation of cell-based therapeutics. We describe the underlying principles governing non-invasive in vivo long-term cell tracking in the preclinical and clinical settings, including available imaging technologies, reporter genes, and imaging agents as well as pitfalls related to experimental design. Our emphasis is on adoptively transferred T cell and stem cell therapies.

KW - adoptive cell therapy

KW - cell tracking

KW - immunotherapy

KW - molecular imaging

KW - prostate-specific membrane antigen

KW - sodium iodide symporter

UR - http://www.scopus.com/inward/record.url?scp=85082816438&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2020.03.016

DO - 10.1016/j.ymthe.2020.03.016

M3 - Review article

C2 - 32243834

AN - SCOPUS:85082816438

SN - 1525-0016

VL - 28

SP - 1392

EP - 1416

JO - Molecular therapy : the journal of the American Society of Gene Therapy

JF - Molecular therapy : the journal of the American Society of Gene Therapy

IS - 6

M1 - 10.1016/j.ymthe.2020.03.016

ER -

Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this